Recent Research Analysts’ Ratings Updates for Certara (CERT)

Certara (NASDAQ: CERT) recently received a number of ratings updates from brokerages and research firms:

• 2/28/2025 – Certara had its price target raised by analysts at Barclays PLC from $12.00 to $13.00. They now have an “equal weight” rating on the stock.
• 2/27/2025 – Certara had its “overweight” rating reaffirmed by analysts at Stephens. They now have a $17.00 price target on the stock.
• 2/27/2025 – Certara had its “market perform” rating reaffirmed by analysts at William Blair.
• 2/27/2025 – Certara is now covered by analysts at TD Cowen. They set a “buy” rating and a $16.00 price target on the stock.

Certara Trading Down 1.1 %

CERT stock traded down $0.13 during mid-day trading on Tuesday, reaching $11.81. The company’s stock had a trading volume of 282,267 shares, compared to its average volume of 1,301,501. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.87. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The business’s 50 day moving average price is $12.48 and its 200 day moving average price is $11.63. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -59.04, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57.

Institutional Trading of Certara

Several hedge funds have recently modified their holdings of the stock. Brown Brothers Harriman & Co. bought a new position in Certara during the third quarter worth $27,292,000. Kopion Asset Management LLC boosted its position in shares of Certara by 46.0% during the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock worth $5,918,000 after purchasing an additional 175,005 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Certara by 40.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock worth $45,691,000 after buying an additional 1,128,006 shares during the period. Vontobel Holding Ltd. bought a new position in Certara in the fourth quarter worth approximately $1,295,000. Finally, Barclays PLC grew its stake in Certara by 198.3% in the third quarter. Barclays PLC now owns 70,525 shares of the company’s stock valued at $825,000 after acquiring an additional 46,880 shares during the period. Institutional investors own 73.96% of the company’s stock.

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.